MedPath

Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma

Phase 2
Completed
Conditions
Effect of Drugs
Adverse Effects of Medical Drugs
Interventions
Drug: 0.9% Normal Saline
Registration Number
NCT04170088
Lead Sponsor
Jinnah Postgraduate Medical Centre
Brief Summary

It is a randomized controlled trial in which investigators determine the efficacy of tranexamic acid (TA) by mesotherapy in comparison to normal saline on participants having Melasma.

Detailed Description

In this prospective single blind split face controlled trial.Total 30 patients referred to Dermatology Ward were selected. At first, patients were examined under wood lamp for determination of melasma type (epidermal, dermal). Then, patients underwent Tranexamic acid microinjections with a concentration of TA 4 mg/ml with 0.9 % normal saline on their left half of the face and only 0.9%normal saline on their right half of the face, with mesotherapy technique. This procedure was done total of six times with 2-week intervals. Participants were assessed by Hemi Modified Melasma Area and Severity Scoring (mMASI) at start and end of the study for each half of face. Statistical Package for Social Sciences (SPSS) , version 23 was used for analysis. P value \< 0.01 was taken significant.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • informed consent
  • age between 18 to 55 years
  • bilateral symmetrical mild to severe melasma
Exclusion Criteria
  • pregnancy and lactation
  • history of taken any topical treatment for melasma in previous 1 month
  • history of bleeding disorders
  • concomitant use of anticoagulants,
  • any known drug allergy especially to the study drug,
  • having associated medical illnesses.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Tranexamic acid0.9% Normal SalineLeft side of face of each participant was selected for intradermal Tranexamic acid injections. generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months
0.9% Normal saline0.9% Normal SalineRight side of face of each participant was selected for intradermal normal saline injections generic name : Normal Saline Dose : 0.9 % Normal Saline Dose : Frequency : every 2 weekly total 6 doses. Duration : 6 months
Tranexamic acidTranexamic AcidLeft side of face of each participant was selected for intradermal Tranexamic acid injections. generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months
Primary Outcome Measures
NameTimeMethod
Change in HEMI-Modified Melasma Area and Severity Index (mMASI)10 months

Calculation of Hemi mMASI score is performed by rating darkness and area of involvement of 3 areas of the each half of face. These figures are then inserted into an equation, resulting in the final Hemi mMASI score for both halves of face. Equation : forehead (0.15×D×A) + malar ( 0.30×D×A) + chin ( 0.05×D×A) The mean value of the data obtained from each half of the face was calculated and the mean percentage change was compared. Hemi-MASI score was used because of the study design of split-face, and it was calculated based on the percentage of the involved area Improvement was considered when there was reduction in mean hemi modified MASI score at both sides of face. Higher score was considered as worse and low score was considered as good in improvement of melasma.

At each follow-up visit, adverse events were also evaluated. Patients were asked to reports side effects such as erythema, burning, swelling, and change in menstrual cycle during and after treatment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jinnah potgraduate Medical Centre ( JINNAH HOPITAL)

🇵🇰

Karachi, Sindh, Pakistan

© Copyright 2025. All Rights Reserved by MedPath